HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information need prescribing information for enoxaparin sodium injection Enoxaparin sodium injection for subcutaneous and intra		Acute STEMI in patients <75 years of age [For dosing in subsequent PCI, see Dosage and Administration [2:1] 30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg SC every 12 hours (with aspirin) 521388 581664
Initial U.S. Approval: 1993		Acute STEMI in patients ≥75 years of age 0.75 mg/kg SC every 12 hours (no bolus) (with aspirin)
See full prescribing im Epidural or spinal hematomas may occur in patients v heparinoids and are receiving neuraxial anesthesia or or permanent paralysis. Consider these risks when so risk of developing epidural or spinal hematomas in th • Use of indveiling epidural catheters • Concomitant use of other drugs that affect h platelet inhibitors, other anticoagulants • A history of traumatic or repeated epidural or • A history of spinal deformity or spinal surger • Optimal timing between the administration of	emostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs spinal punctures / enoxaparin sodium and neuraxial procedures is not known. neurological impairment. If neurological compromise is noted, urge	Project the does not patients with service relian impainment (2.2., 0.7) DOSAGE FORMS AND STRENGTHS 100 mg/mL concentration (3.1): Prefilied syringes: 30 mg/0.3 mL, 40 mg/0.4 mL Graduated prefilied syringes: 120 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL, 150 mg/1 mL Graduated prefilied syringes: 120 mg/0.8 mL
DECE	NT MAJOR CHANGES	 Hypersensitivity to enoxaparin sodium (4) Hypersensitivity to heparin or pork products (4)
Boxed Warning Warnings and Precautions (5.1)	10/1: 10/1: 10/12	Hypersensitivity to benzyl alcohol [for multi-dose formulation only] (4)
Enoxaparin sodium is a low molecular weight heparin (LMW Prophylaxis of deep vein thrombosis (DVT) in abdomi replacement surgery, or medical patients with severe Inpatient treatment of acute DVT with or without pulm Outpatient treatment of acute DVT without pulmonary Prophylaxis of ischemic complications of unstable and Treatment of acute ST-segment elevation myocardial percutaneous coronary intervention [PC] (1.4)	H] indicated for: nal surgery, hip replacement surgery, knee y restricted mobility during acute illness (1.1) onary embolism (1.2) embolism (1.2)	Percutaneous coronary revascularization: Obtain hemostasis at the puncture site before sheath removal (5.2) Concomitant medical conditions: Use with caution in patients with bleeding diathesis, uncontrolled arterial hypertension or history of recent gastrointestinal ulceration, diabetic retinopathy, renal dystunction, or hemorrhage (5.3) History of heparin-induced thrombocytopenia: Use with caution (5.4) Thrombocytopenia: Monitor thrombocytopenia closely (5.5) Interchangeability with other heparines. Do not exchange with heparin or other LMWHs (5.6) Pregnant women with mechanical prosthetic heart valves and their fetuses, may be at increased risk and may need more frequent monitoring and dosage adjustment (5.7) ADVERSE REACTIONS
Indication	Dose	Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, and
DVT prophylaxis in abdominal surgery	40 mg SC once daily	nausea (6.1)
DVT prophylaxis in knee replacement surgery	30 mg SC every 12 hours	To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance & Medical Affairs at 1-800-551-7176 o FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch</u> .
DVT prophylaxis in hip replacement surgery	30 mg SC every 12 hours or 40 mg SC once daily	DRUG INTERACTIONS DIScontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium or conduct close clinical and laboratory monitoring (£ 0, 7)
DVT prophylaxis in medical patients	40 mg SC once daily	monitoring (5.9, 7) USE IN SPECIFIC POPULATIONS
Inpatient treatment of acute DVT with or without pulmonary embolism	1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily*	Severe Renal Impairment: Adjust dose for patients with creatinine clearance <30mL/min (2.2, 8.7) Geriatric Patients: Monitor for increased risk of bleeding (8.5) Patients with mechanical heard values: Not adjourable studied (8.6)
Outpatient treatment of acute DVT without pulmonary embolism	1 mg/kg SC every 12 hours*	 Hepatic Impairment: Use with caution. (8.8) Low-Weight Patients: Observe for signs of bleeding (8.9)
Unstable angina and non-Q-wave MI	1 mg/kg SC every 12 hours (with aspirin)	Obese Patients: Not adequately studied. Observe for thromboembolism (8.10) See 17 for PATIENT COUNSELING INCOMMUNE

See 17 for PATIENT COUNSELING INFORMATION

USE IN SPECIFIC POPULATIONS

Renal Impairment

8.9 Low-Weight Patients 8.10 Obese Patients 0VERDOSAGE

CLINICAL PHARMACOLOGY

NONCLINICAL TOXICOLOGY

Hepatic Impairment

Mechanism of Action

Pharmacodynamics Pharmacokinetics

SPECIFIC PUPULATIONS Pregnancy Nursing Mothers Pediatric Use Geriatric Use Patients with Mechanical Prosthetic Heart Valves Patients with Mechanical Prosthetic Heart Valves

11/2014

FULL PRESCRIBING INFORMATION: CONTENTS' WARNING: SPINAL / EPIDURAL HEMATOMAS

- INDICATIONS AND USAGE
- INDICATIONS AND USAGE

 1.1
 Prophylaxis of Deep Vein Thrombosis

 1.2
 Treatment of Acute Deep Vein Thrombosis

 1.3
 Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction

 1.4
 Treatment of Acute S-Segment Elevation Myocardial Infarction

 DOSAGE AND ADMINISTRATION
 Description

2

- 22
- Adult Dosage Renal Impairment Geriatric Patients with Acute ST-Segment Elevation Myocardial Infarction
- 2.4 Administration DOSAGE FORMS AND STRENGTHS 3
- 100 mg/mL Concentration
- 150 mg/mL Concentration
- CONTRAINDICATIONS 4
- INGS AND PRECAUTIONS
- Increased Risk of Hemorrhage Percutaneous Coronary Revascularization Procedures 5.2
- 5.3 Use of Enoxaparin sodium with Concomitant Medical Conditions
- 5.4
- 5.5 5.6
- History of Heparin-Induced Thrombocytopenia Thrombocytopenia Interchangeability with Other Heparins Pregnant Women with Mechanical Prosthetic Heart Valves
- 5.8 5.9 Benzyl Alcohol
- Laboratory Tests
- ADVERSE REACTIONS
- 6.1 Clinical Trials Experience 6.2 Postmarketing Experience DRUG INTERACTIONS

FULL PRESCRIBING INFORMATION

WARNING: SPINAL/EPIDURAL HEMATOMAS

Epidural or spinal hematomas may occur in patients who are anticoaquitated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters

risk of developing épidural or spinal hematomas in these patients include:
Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticcagulants
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery
Optimal timing between the administration of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients anticcagulated or to be anticcagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7]].

INDICATIONS AND USAGE

- Prophylaxis of Deep Vein Thrombosis
 Prophylaxis of Deep Vein Thrombosis (DVT), which may lead to pulmonary embolism (PE):
 in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see *Clinical Studies* (14.1]].

- in patients undergoing to replacement surgery, during and following hospitalization. in patients undergoing this replacement surgery. in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.

1.2 Treatment of Acute Deep Vein Thrombosis Enoxaparin sodium is indicated for:

- The impatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium. The <u>outpatient treatment</u> of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with documents of the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with documents of the outpatient treatment of acute deep vein thrombosis without pulmonary embolism.

warfarin sodium.

The number of the second se

when concurrently administered with aspirin.
1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction
Enoxaparin sodium, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction (STEM) receiving thrombolysis and being managed medically or with perculaneous coronary intervention (PC).
2 DOSAGE AND ADMINISTRATION

All patients should be evaluated for a bleeding disorder before administration of enoxaparin sodium, unless the medication is needed urgently. Since coagulation parameters are unsuit not required [see Warnings and Precautions (5.9]]. uitable for monitoring enoxaparin activity, routine monitoring of coagulation parameters is

Carcinogenesis, Mutagenesis, Impairment of Fertility Animal Toxicology and/or Pharmacology 13.2 13.3 Reproductive and Developmental Toxicology 14 CLINICAL STUDIES

8

10 11

12

13

8.1

8.3

8.4 8.5 8.6 8.7

8.8

12.1

12.2

12.3

13.1

DESCRIPTION

- AL STUDIES Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Prophylaxis of Deep Vein Thrombosis with or Windour Patholic Medical Patients with Severely Restricted Mobility During Acute Illness Treatment of Deep Vein Thrombosis with or Windour Putholary Embolism Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction 14.1 14.2 14.3
- 14.4 14.5
- 14.6 Treatment of Acute ST-Segment Elevation Myocardial Infarction HOW SUPPLIED/STORAGE AND HANDLING

16

PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

For subcutaneous use, enoxaparin sodium should not be mixed with other injections or infusions. For intravenous use (i.e., for treatment of acute STEMI), enoxaparin sodium can be mixed with normal saline solution (0.9%) or 5% dextrose in water. Enoxaparin sodium is not intended for intramuscular administration.

2.1 Adult Dosage Abdominal Surgery. In patients undergoing abdominal surgery who are at risk for thromboembolic complications, the recommended dose of enoxaparin sodium is 40 mg once a day administered by SC injection with the initial dose given 2 hours prior to surgery. The usual duration of administration is 7 to 10 days; up to 12 days administration has been administered in clinical trials. *Hij or Knee Replacement Surgery*: In patients undergoing hip or knee replacement surgery. The recommended dose of enoxaparin sodium is 30 mg every 12 hours administered by SC injection. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. Group the preplacement surgery, and so ef 40 mg once a day SC, given initially 12 (±3) hours prior to surgery. may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, it is recommended that continued prophylaxis with enoxaparin sodium 40 mg once a day administered by SC injection or 3 weeks. The usual duration of administration is 7 to 10 days; up to 14 days administration has been administered by SC injection for 3 weeks. The usual duration of administration is 6 to 11 days; up to 14 days of enoxaparin sodium s 40 mg once a day administered by SC injection. The usual duration of administration is 6 to 11 days; up to 14 days of enoxaparin sodium s 40 mg once a day administered in clinical trials. *Medical Patients During Acute Illness*, the recommended dose of enoxaparin sodium s 40 mg once a day administered by SC injection. The usual duration of administration is 6 to 11 days; up to 14 days of enoxaparin sodium has been administered in the controlled clinical trial.

clinical trial. <u>Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism</u>: In **outpatient treatment**, patients with acute deep vein thrombosis without pulmonary embolism who can be treated at home, the recommended dose of enoxaparin sodium is 1 **mg/kg every 12 hours** administered SC. In **inpatient (Inospital) treatment**, patients with acute deep vein thrombosis without pulmonary embolism or patients with acute deep vein thrombosis without pulmonary embolism (who are not candidates for outplatient treatment), the recommended dose of enoxaparin sodium is **1 mg/kg every 12 hours** administered SC **or 1.5 mg/kg once a day** administered SC at the same time every day. In both outpatient and inpatient (hospital) treatments, warfarin sodium therapy should be unitated when appropriate (usually within 72 hours of enoxaparin sodium). Enoxaparin sodium should be continued for a minimum of 5 days and until a therepautic oral anticoagulant effect has been achieved (international Normalization Ratio 2.0 to 3.0). The average duration of administration is 7 days; up to 17 days of enoxaparins fordium. days of enoxaparin sodium administration has been administered in controlled clinical trials.

days of enoxaparin sodium administration has been administered in controlled clinical trials. <u>Unstable Angina and Mon-UNave Moocardial Infraction</u>: In patients with unstable angina or non-O-wave myocardial infraction, the recommended dose of enoxaparin sodium is **1 mg/kg** administered SC **every 12 hours** in conjunction with oral aspirin therapy (100 to 325 mg once daily). Treatment Awith enoxaparin sodium should be prescribed for a minimum of 2 days and continued until clinical stabilization. The usual duration of treatment is **2** to 8 days, up to 125 days of enoxaparin sodium has been administered and continued until clinical stabilization. The usual duration of treatment is **2** to 8 days, up to 125 days of enoxaparin sodium has been administered inclinical trials (see Warnings and Precaufions (3.2) and Clinical Studies (14.5)]. <u>Treatment of Aucli ST-Segment Elevation Myocardial Infraction</u>: In patients with acute ST-segment elevation myocardial infraction, the recommended dose of enoxaparin sodium is a **single IV bolius of 30 mg** plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg dosing for the remaining doses). Dosage adjustments are recommended in patients x75 years of age [see Dosage and Administration (2.3)]. All patients should receive aspirin as soon as they are identified as having STEMI and maintained with 75 to 325 mg once daily unless contraindicated. When administered in conjunction with a trombol/tic (fibrin-specific) er on-n-fibrin specific), enoxaparin sodium should be given between

When administered in conjunction with a trombulytic (fibrin-specific or non-fibrin specific), enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy. In the pivotal clinical study, the enoxaparin sodium treatment duration was 8 days or until hospital discharge, whichever came first. An optimal duration of treatment is not known, but it is likely to be longer than 8 days. For patients managed with prevataneous coronary intervention (PC) if the last enoxaparin sodium SC administration was given less than 8 hours before balloon inflation, no additional dosing is needed. If the last enoxaparin sodium SC administration was given more than 8 hours before balloon inflation, an V bolus of 0.3 mg/kg of enoxaparin sodium should be administered [see Warnings and Precautions (5.2]).

2.2 Renal Impairment

Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30-50 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding. The recommended prophysias and treatment dosage regimens for patients with severe renal impairment (creatinine clearance <30 mL/min) are described in Table 1 [see Use in Specific Populations (8.7) and *Clinical Pharmacology* (12.3].

Table 1

Dosage Regimens for Patients with Severe Renal Impain	nent (creatinine clearance <30mL/minute)
Indication	Dosage Regimen
Prophylaxis in abdominal surgery	30 mg administered SC once daily
Prophylaxis in hip or knee replacement surgery	30 mg administered SC once daily
Prophylaxis in medical patients during acute illness	30 mg administered SC once daily
Inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium	1 mg/kg administered SC once daily
Outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium	1 mg/kg administered SC once daily
Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin	1 mg/kg administered SC once daily
Treatment of acute ST-segment elevation myocardial infarction in patients <75 years of age, when administered in conjunction with aspirin	30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC once daily.
Treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, when administered in conjunction with aspirin	1 mg/kg administered SC once daily (no initial bolus)

2.3 Geriatric Patients with Acute ST-Segment Elevation Myocardial Infarction

2.5 behave raterits with Acute 31-segment revaluent important influence in a perfait particular in a cute of the segment and the second in traction in a perfait particular is ≥75 years of age, do not use an initial IV bolus. Initiate dosing with 0.75 mg/kg 52 every 12 hours (maximum 75 mg for the first two doses only, followed by 0.75 mg/kg dosing for the remaining doses) (see Use in Specific Populations (8.5) and Chinical Pharmacology (12.3). No dose adjustment is necessary for other indications in genatic patients unless kidney function is impaired [see Dosage and Administration of the second provide the second

2.4 Administration

Enoxaparin sodium injection is a clear, colorless to pale vellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration

The use of a tuberculin syringe or equivalent is recommended when using enoxaparin sodium multiple-dose vials to assure withdrawal of the appropriate volume of drug.

Enoxaparin sodium must not be administered by intramuscular injection. Enoxaparin sodium is intended for use under the guidance of a physician

Enotagani sodium must not be administered by intramuscular injection. Enotagani sodium si intended for use under the gludance of a physician. For subcutaneous administration, patients may self-inject only if their physicians determine that it is appropriate and with medical follow-up, as necessary. Proper training in subcutaneous injection technique (with or without the assistance of an injection device) should be provided. <u>Subcutaneous Injection Technique</u>: Patients should be lying down and enoxaparin sodium administered by deep SC injection. To avoid the loss of drug when using the 30 and 40 mg perilled syringes, do not expel the air bubble from the syringe before the injection. Administration should be alternated between the left and right attracturat and left and right posterolateral addominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not nub the injection site after completion of the injection.

Enoxaparin sodium prefilled syringes and graduated prefilled syringes are for single, one-time use only and are available with a system that shields the needle after injection.

Remove the prefilled syringe from the blister packaging by peeling at the arrow as directed on the blister. Do not remove by pulling on the plunger as this may damage the syringe

 Remove the needle shield by pulling it straight off the syringe (see Figure A). If adjusting the dose is required, the dose adjustment must be done prior to injecting the prescribed dose to the patient

2. Inject using standard technique, pushing the plunger to

Figure A

Figure B



the bottom of the syringe (see Figure B).

and and

activate the safety system by firmly pushing the plunger rod. The protective sleeve will automatically cover the needle and an audible "click" will be heard to confirm shield activation (see Figure D). Figure D

4. Orient the needle away from you and others, and



5. Immediately dispose of the syringe in the nearest sharps container (see Figure E)



Remove the syringe from the injection site keeping you finger on the plunger rod (see Figure C)



NOTE

- The safety system can only be activated once the syringe has been emptied
- Activation of the safety system must be done only after removing the needle from the patient's skin
 - Do not replace the needle shield after injection.

 The safety system should not be sterilized.
 Activation of the safety system may cause minimal splatter of fluid. For optimal safety activate the system while orienting it downwards as from yourself and others. Intravenous (Bolus) Injection Technique: For intravenous injection, the multiple-dose vial should be used. Enoxaparin sodium should be

administered through an intravenous line. Enoxaparin sodium should not be mixed or co-administered with other medications. To avoid the possible mixture of enoxaparin sodium with other drugs, the intravenous access chosen should be flushed with a sufficient amount of saline or dextrose solution prior to and following the intravenous blous administration of enoxaparin sodium to clear the port of drug. Enoxaparin sodium may be safely administered with normal saline solution (0.9%) or 5% dextrose in water. 3 DOSAGE FORMS AND STRENGTHS

ia available in two e

Enoxaparin socialin injection is available in two concentrations.	
3.1 100 mg/mL Concentration	
-Prefilled Syringes	30 mg/0.3 mL, 40 mg/0.4 mL
-Graduated Prefilled Syringes	60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL
-Multiple-Dose Vials	300 mg/3 mL
3.2 150 mg/mL Concentration	
-Graduated Prefilled Syringes	120 mg/0.8 mL, 150 mg/1 mL
4 CONTRAINDICATIONS	
Active major bleeding	

- Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium
- Informacy operate associated with a positive in multicle to an impactive anabody in the presence of encoderant social in social fields. Known hypersensitivity to encoderation social (e.g., puritis, uricaria, anaphylactic/anaphylactoid reactions) [see Adverse Reactions (6.2]] Known hypersensitivity to heparin or pork products

Known hypersensitivity to benzyl alcohol (which is in only the multi-dose formulation of enoxaparin sodium [see Warnings and Precautions (5.8)]

WARNINGS AND PRECAUTIONS

5 Warking SAU Precision in the second sec Drug Interactions (7)].

To reduce the potential risk of bleeding associated with the concurrent use of enoxaparin sodium and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of enoxaparin [see *Clinical Pharmacology* (*12.3*], Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticcagulant effect of enoxaparin is low; however, the exact timing to reach a sufficiently low anticcagulant effect in each natient is not kno

Hacement or removal of a catheter should be delayed for at least 12 hours after administration of lower doses (30 mg once or twice daily or 40 mg once daily) of enoxaparin sodium and at least 24 hours after the administration of higher doses (0.75 mg/kg twice daily, 1 mg/kg twice daily, or 1.5 mg/kg 3

once daily) of enoxaparin sodium. Anti-Xa levels are still delectable at these time points, and these delays are not a guarantee that neuraxial hematoma will be avoided. Patients receiving the 0.75 mg/kg twice daily dose or the 1 mg/kg twice daily dose should not receive the second enoxaparin sodium dose in the twice daily regimen to allow a longer delay before catheter placement or removal. Likewise, although a specific recommendation for timing of a subsequent enoxaparin sodium dose after catheter removal cannot be made, consider delaying this next dose for at least four hours, based on a benefit-risk assessment considering both the risk for thrombosis and the risk for bleeding in the context of the procedure and patient risk factors. For patients with creatimic clearance -20mL/minute, additional considerations are necessary because elimination of enoxaparin is more prolonged; consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of enoxaparin sodium (30 mg once daily) and at least 48 hours for the higher dose (1 mg/kg/dw) [see Clinitar] *Phramacology* (12.3). Should the physician decide to administer anticcagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, enserory and motor deficits (numbress or weakness in lower introls), bowel and/or bladder dystruction. Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae. once daily) of enoxaparin sodium. Anti-Xa levels are still detectable at these time points, and these delays are not a guarantee that neuraxial hematoma

Enoxaparin sodium should be used with extreme caution in conditions with increased risk of hemorrhage, such as bacterial endocarditis. Encorpanin solum should be used winn extreme caution in conductors with increased risk or nemotrage, subcording as decremate endocadruids, congenital or acquired bleeding disorders, active uclerative and angiosylpasitic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors. Major hemorrhages including retroperitoneal and intracranial bleeding have been reported. Some of these cases have been fatal. Bleeding can occur at any site during therapy with enovaparin sodium. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site.

5.2 Percutaneous Coronary Revascularization Procedures

5.2 Percutaneous Coronary Revascularization Procedures To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, non-Q-wave myocardial infarction and acute ST-segment elevation myocardial infarction, adhere precisely to the intervals recommended between enoxaparin sodium doses. It is important to achieve hemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6 hours after the tast IVSC enoxaparin sodium. If the treatment with enoxaparin sodium is to be continued, the next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal. The site of the procedure should be observed for signs of bleeding or hematoma formation [see Dosage and Administration (2.1).

5.3 Use of Enoxaparin sodium with Concomitant Medical Conditions

Enoxaparin sodium should be used with care in patients with a bleeding diathesis, uncontrolled arterial hypertension or a history of recent gastrointestinal ulceration, diabetic retinopathy, renal dysfunction and hemorrhage. 5.4 History of Henarin-Induced Thrombocytonenia

sodium should be used with extreme caution in patients with a history of heparin-induced thrombocytopenia

5.5 Thrombocytopenia

Thrombocytopenia can occur with the administration of enoxaparin sodium

Informocytopenia can occur with the administration of enoxaparin sodium. Moderate thromocytopenia (platelet counts between 100,000/mm³) and 50,000/mm³) occurred at a rate of 1.3% in patients given enoxaparin sodium, 1.2% in patients given heparin, and 0.7% in patients given placebo in clinical trials. Platelet counts less than 50,000/mm³ occurred at a rate of 0.1% in patients given enoxaparin sodium, in 0.2% of patients given heparin, and 0.4% of patients given placebo in the same trials. Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm³, enoxaparin sodium should be discontinued. Cases of heparin-induced thrombocytopenia with thrombosis have also been observed in clinical practice. Some of these cases were complicated by organ infarction, limb ischemia, or death [*see Warnings and Precautions (5.4*].

So furch again the control of the source of

5.7 Pregnant Women with Mechanical Prosthetic Heart Valves

The use of enovaparin sodium for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. In a clinical study of pregnant women with mechanical prosthetic heart valves given enovaparin (1 mg/kg twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and fetal death. Although a causal relationship has not been established these deaths may have been due to therapeutic failure or inadequate anticoagulation. No patients in the reasurusmp nas nou eere estanismed mese deaths may have been due to therapeutic failure or inadequate anticoagulation. No patients in the heparin/warfarin group (0 of 4 women) died. There also have been isolated postmarketing reports of valve thrombosis in pregnant women with mechanical prosthetic heart valves while receiving enoxaparin for thromboprophylaxis. Women with mechanical prosthetic heart valves may be at higher risk for thromboembolism during pregnancy, and, when pregnant, have a higher rate of fetal loss from stillbirth, spontaneous abortion and premature delivery. Therefore, frequent monitoring of peak and trough anti-Factor Xa levels, and adjusting of dosage may be needed [see Use in Specific Populations (8.6]].

5.8 Benzyl Alcoho

3.0 beildy audition Encorpanis odium multiple-dose vials contain benzyl alcohol as a preservative. The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal "gasping syndrome". Because benzyl alcohol may cross the placenta, encorparins douting multiple-dose vials, preserved with benzyl alcohol, should be used with caution in pregnant women and only if clearly needed [see Use in Specific Populations (8.1)].

5.9 Laboratory Tests

Periodic complete blood counts, including platelet count, and stool occult blood tests are recommended during the course of treatment Periodic complete blood counts, including platelet count, and stool occuit blood tests are recommended ouring the course or treatment with encoxpairs osdium. When administered at recommended prophylaxis doese, routine coagulation tests such as Prothrombin Time (P) and Activated Partial Thromboplastin Time (aPTT) are relatively insensitive measures of encoxparin activity and, therefore, unsuitable for monitoring. Anti-Factor Xa may be used to monitor the anticoagulant effect of encoxparin sodium triang attention the anticoagulant effect of encoxparin sodium transparin sodium transparin sodium transparin sodium transparing attention the anticoagulant effects of encoxparin sodium (see *Clinical Pharmacology (12.3)*.

ADVERSE REACTIONS 6.1 Clinical Trials Experience

- The following serious adverse reactions are also discussed in other sections of the labeling:

directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. During clinical development for the approved indications, 15,918 patients were exposed to envaparin sodium. These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hadominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hadominal surgery in patients at risk for thromhoembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hadominal surgery in patients at risk for thromhoembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hadominal surgery in patients at risk for the approxed in an endical platents with severely restricted mobility during acute lines, 1,578 for prophylaxis of schemic complications in unstand or hip or knee replacement surgery or in medical platents with severely restricted mobility during acute illness ranged from 40 mg SC once daily to 30 mg SC twice daily. In the clinical studies for prophylaxis of unstable angina and non-Q-wave myocardial inflarction doese were 1 mg/kg every 12 hours and in the clinical studies for treatment of acute ST-segment elevation myocardial inflarction envoganin sodium doeses were a 30 mg IV blous followed by 1 mg/kg every 12 hours SC.

Hemorrhage

The incidence of major hemorrhagic complications during enoxaparin sodium treatment has been low.

The following rates of major bleeding events have been reported during clinical trials with enoxaparin sodium [see Tables 2 to 7].

Table 2 Major Bleeding Episodes Following Abdominal and Colorectal Surgery¹

		Dosing Regimen			
Indications	Enoxaparin Sodium 40 mg q.d. SC	<u>Heparin</u> 5000 U q8h SC			
Abdominal Surgery	n = 555 23 (4%)	n = 560 16 (3%)			
Colorectal Surgery	n = 673 28 (4%)	n = 674 21 (3%)			

Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transtusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered mai

			Idu	16.2			
Ν	lajor Bleeding	Episodes	Following	Hip o	r Knee	Replacement	Surgery ¹

		Dosing Regimen	
Indications	Enoxaparin Sodium	Enoxaparin Sodium	<u>Heparin</u>
	40 mg q.d. SC	30 mg q12h SC	15,000 U/24h SC
Hip Replacement Surgery		n = 786	n = 541
without Extended Prophylaxis ²		31 (4%)	32 (6%)
Hip Replacement Surgery with Extended Prophylaxis Peri-operative Period ³	n = 288 4 (2%)		
Extended Prophylaxis Period ⁴	n = 221 0 (0%)		
Knee Replacement Surgery		n = 294	n = 225
without Extended Prophylaxis ²		3 (1%)	3 (1%)

Bleeding complications were considered major; (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a Decomp Computations where considered in age, if in the health and every a significant contrast event, or (c) in accompanies of a hemoglobin decrease > 2 g/d) or translusion of 2 or more units of blood products. Streboertioneal and initracranial hemorrhages were also considered major hemorrhages. Considered major. In the knee replacement surgery trials, intraccular hemorrhages were also considered major hemorrhages. Proxaparin sodium 30 mg every 12 hours Sc initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery ³ Enoxaparin sodium 40 mg SC once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgery ⁴ Enoxaparin sodium 40 mg SC once a day for up to 21 days after discharge

NOTE: At no time point were the 40 mg once a day pre-operative and the 30 mg every 12 hours post-operative hip replacement surgery prophylactic regimens compared in clinical trials. Injection site hematomas during the extended prophylaxis period after hip replacement surgery occurred in 9% of the enoxaparin patients versus

major bieeding Episodes in medic	al Paueills with Severely Re	estricted mobility During Ac	ute mness
		Dosing Regimen	
Indications	Enoxaparin Sodium ² 20 mg q.d. SC	Enoxaparin Sodium ² 40 mg q.d. SC	<u>Placebo²</u>
Medical Patients During Acute Illness	n = 351 1 (<1%)	n = 360 3 (<1%)	n = 362 2 (<1%)

¹ Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial

² The rates represent major bleeding on study medication up to 24 hours after last dose Table 5

1.8% of the placebo patients

Major Bleeding Episodes in Deep Vein Thrombosis with or without Pulmonary Embolism Treatment

		Dosing Regimen ²				
Indication	<u>Enoxaparin</u>	Enoxaparin	<u>Heparin</u>			
	<u>Sodium</u>	Sodium	aPTT Adjusted			
	1.5 mg/kg q.d. SC	1 mg/kg q12h SC	IV Therapy			
Treatment of DVT and PE	n = 298	n = 559	n = 554			
	5 (2%)	9 (2%)	9 (2%)			

Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglob decrease > 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were alway considered major.

² All patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of enoxaparin sodium or standard heparin therapy and continuing for up to 90 days. Table 6

Major Bleeding Episodes in Unstable Angina and Non-Q-Wave Myocardial Infarction

	Dosing Regimen				
Indication	Enoxaparin Sodium ¹ 1 mg/kg q12h SC	Heparin ¹ aPTT Adjusted IV Therapy			
Unstable Angina and Non-Q-Wave MI ^{2,3}	n = 1578 17 (1%)	n = 1529 18 (1%)			

¹ The rates represent major bleeding on study medication up to 12 hours after dose. ² Aspirin therapy was administered concurrently (100 to 325 mg per day).

³ Bleeding complications were considered maior: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by $\ge 3 \text{ g/dL}$ or transfusion of 2 or more units of blood products. Intraocular, retroperitoneal, and intracranial her hages were always considered major

Table 7 Major Disading Enjandes in Asuto

	Dosing Regimen				
Indication	Enoxaparin Sodium ¹ Initial 30 mg IV bolus followed by 1 mg/kg q12h SC	Heparin ¹ aPTT Adjusted IV Therapy			
Acute ST-Segment Elevation Myocardial Infarction	n = 10176 n (%)	n = 10151 n (%)			
- Major bleeding (including ICH) ²	211 (2.1)	138 (1.4)			
- Intracranial hemorrhages (ICH)	84 (0.8)	66 (0.7)			

¹The rates represent major bleeding (including ICH) up to 30 days ² Bleedings were considered major if the hemorrhage caused a significant clinical event associated with a hemoglobin decrease by ≥ 5 g/dL. ICH were always considered major.

Elevations of Serum Aminotransfer

Levations of Serum Ammotransterases Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients, respectively, during treatment with encoxpanin sodium. Similar significant increases in aminotransferase levels have also been observed in patients and healthy volunteers treated with heparin and other low molecular weight heparins. Such elevations are fully reversible and are rarely associated with increases in bilinubin. Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction. liver disease, and pulmonary emboli.

elevations that might be caused by drugs like enoxaparin sodium should be interpreted with caution. Local Reactions

Local Reactions Mild local irritration, pain, hematoma, ecctymosis, and erythema may follow SC injection of enoxaparin sodium. Adverse Reactions in Patients Receiving Enoxaparin Sodium for Prophylaxis or Treatment of DVT, PE: Other adverse reactions that were thought to be possibly or probably related to treatment with enoxaparin sodium, heparin, or placebo in clinical triak with patients undergoing hip or knee replacement surgery, adoximinal or colorectal surgery, or treatment for DVT and that occurred at a rate of at least 2% in the enoxaparin group, are provided below [see Tables 8 to 11].

least 2/8 III till e invaparin group, are provinced berow peer names o w +1, Table 8 Adverse Reactions Occurring at ≥2% Incidence in Enoxaparin-Treated Patients Undergoing Abdominal or Colorectal Surgery

		Dosing Regimen				
	Enoxapari 40 mg n = 1 9	q.d. SC 1228	Heparin 5000 U q8h SC n = 1234 %			
Adverse Reaction	Severe			Total		
Hemorrhage	<1	7	<1	6		
Anemia	<1	3	<1	3		
Ecchymosis	0	3	0	3		
	Table	e 9	·			

Adverse Reactions Occurring at >2% Incidence in Enoxan ated Patients Undergoing Hip or Knee Replacement Surger

		Dosing Regimen								
		Enoxaparin 40 mg q			Enoxa Sod 30 mg S	q12h	<u>Hep</u> 15,000 S	U/24h	<u>Plac</u> q12t	
	Peri-op Peri n = 2	od 88 ¹	Proph Per	nded ıylaxis iod 131 ² 6	n = '9		n =	766 %	n =	
Adverse Reaction	Severe	Total	Severe	Total	Severe	Total	Severe	Total	Severe	Total
Fever	0	8	0	0	<1	5	<1	4	0	3
Hemorrhage	<1	13	0	5	<1	4	1	4	0	3
Nausea					<1	3	<1	2	0	2
Anemia	0	16	0	<2	<1	2	2	5	<1	7
Edema					<1	2	<1	2	0	2
Peripheral edema	0	6	0	0	<1	3	<1	4	0	3

¹ Data represent enoxaparin sodium 40 mg SC once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received enoxaparin sodium peri-operatively in an unblinded fashion in one clinical trial.

² Data represent enovaparin sodium 40 mg SC once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial.

5

enoxaparin sodium injection

521388 581664

Table 10 Adverse Reactions Occurring at ≥2% Incidence in Enoxaparin-Treated Medical Patients with Severely Restricted Mobility During Acute Illness

	Dos	sing Regimen
Adverse Reaction	Enoxaparin Sodium 40 mg q.d. SC n = 360 %	Placebo q.d. SC n = 362 %
Dyspnea	3.3	5.2
Thrombocytopenia	2.8	2.8
Confusion	2.2	1.1
Diarrhea	2.2	1.7
Nausea	2.5	1.7

Table 11 verse Reactions Occurring at ≥2% In xaparin-Treated Patients Undergoing cidence in

			Dosing I	Regimen			
	1.5 mg/k n =	Enoxaparin Sodium Enoxaparin Sodium 1.5 mg/kg q.d. SC 1 mg/kg q12h SC n = 298 n = 559 % %				Heparin aPTT Adjusted IV Therapy n = 544 %	
Adverse Reaction	Severe	Total	Severe	Total	Severe	Total	
Injection Site Hemorrhage	0	5	0	3	<1	<1	
Injection Site Pain	0	2	0	2	0	0	
Hematuria	0	2	0	<1	<1	2	

Adverse Events in Enoxaparin-Treated Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction:

Non-hemorrhagic clinical events reported to be related to enoxaparin sodium therapy occurred at an incidence of \leq 1%. Non-major hemorrhagic clinical events reported to be related to enoxaparin sodium therapy occurred at an incidence of \leq 1%. Non-major hemorrhagic events, primarily injection site ecchymoses and hematomas, were more frequently reported in patients treated with SC enoxaparin sodium than in patients treated with V heparin. enoxaparn socium than in patients treated with V heparin. Services adverse ventisk with oroxparin socium or heparin in a clinical trial in patients with unstable angina or non-Q-wave myocardial infarction that occurred at a rate of at least 0.5% in the enoxaparin group are provided below [see Table 12]. Table 12 Serious Adverse Events Occurring at 2.05% Incidence in Enoxaparin-Treated Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction

	Dosing Regimen		
	Enoxaparin Sodium 1 mg/kg q12h SC n = 1578	Heparin aPTT Adjusted IV Therapy n = 1529	
Adverse Event	n (%)	n (%)	
Atrial fibrillation	11 (0.70)	3 (0.20)	
Heart failure	15 (0.95)	11 (0.72)	
Lung edema	11 (0.70)	11 (0.72)	
Pneumonia	13 (0.82)	9 (0.59)	

Adverse Reactions in Enoxaparin-Treated Patients with Acute ST-Segment Elevation Myocardial Infarction: In a clinical trial in patients with acute ST-segment elevation myocardial infarction, the only adverse reaction that occurred at a rate of at least 0.5% in the enoxaparin group was thrombocytopenia (1.5%).

6.2 Postmarketing Experience

b.2 rosmanceung expensive The following adverse reactions have been identified during postapproval use of enoxaparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug expo

There have been reports of epidural or spinal hematoma formation with concurrent use of enoxaparin sodium and spinal/epidural anesthesia or spinal puncture. The majority of patients had a post-operative indwelling epidural catheter placed for analgesia or received additional drugs affecting hemostasis such as NSAIDs. Many of the epidural or spinal hematomas caused neurologic injury, including long-term or permanent paralysis

Local reactions at the injection site (e.g. nodules, inflammation, oozing), systemic allergic reactions (e.g. pruritus, urticaria, anaphylactic/ anaphylacticid reactions including shock), vesiculobulious rash, rare cases of hypersensitivity cutaneous vasculitis, purpura, skin necrosis (occurring at either the injection site or distant from the injection site), thrombocytosis, and thrombocytopenia with thrombosis [see Warnings and Precautio ins (5.5)] have been reported.

Precations (5.5) have been reported. Cases of hyperkalemia have been reported. Most of these reports occurred in patients who also had conditions that tend toward the development of hyperkalemia (e.g., renal dysfunction, concomitant polassium-sparing drugs, administration of potassium, hematoma in body tissues). Very rare cases of hyperkipidemia have also been reported, with one case of hyperkipidemia, with marked hypertriglyceridemia, reported in a diabetic pregnant woman; causality has not been determined. Cases of headcathe, hemorthagic caremia, escinophilia, alopecia, hepatocellular and cholestatic liver injury have been reported. Stepoprosis has also been reported following long-term therapy. 7 DINE MERGETIONES

VIDENDIFICATIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium therapy. These agents include medications such as: anticoagulants, platletel inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or suffinyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.9].

USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

prognancies have a background risk of birth defect, loss, or other adverse outcome regardless of drug exposure. The fetal k summary below describes the potential of enoxaparin sodium to increase the risk of developmental abnormalities above background risk.

Fetal Risk Summary

Encompain does not cross the placenta, and is not expected to result in fetal exposure to the drug. Human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin sodium does not increase the risk of major developmental abnormalities. Based on animal data, enoxaparin is not predicted to increase the risk of major developmental abnormalities (see Data). Clinical Considerations

<u>Unical Considerations</u> Prepanary alone confers an increased risk for thromboembolism that is even higher for women with thromboembolic disease and certain high risk pregnancy conditions. While not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for thrombosis [see Warnings and Precautions (5.7) and Use in Specific Populations (8.6)]. Pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired thrombophilias, have an increased risk of other maternal complications and fetal loss regardless of the type of anticoagulant used.

All patients receiving anticoaquiates of use type of anticoaquiant user. All patients receiving anticoaquiants, including pregnant women, are at risk for bleeding. Pregnant women receiving enoxaparin should be carefully monitored for evidence of bleeding or excessive anticoaquilation. Consideration for use of a shorter acting anticoaquilant should be specifically addressed as delivery approaches [see *Boxed Warning*]. Hemorthage can occur at any site and may lead to death of mother and/or fetus. Pregnant women should be apprised of the potential hazard to the fetus and the mother if enoxaparin is administered during pregnancy. It is not known if monitoring of anti-Factor Xa activity and dose adjustment (by weight or anti-Factor Xa activity) of enoxaparin sodium affect the safety and the efficacy of the drug during pregnancy.

Cases of "gasping syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99-405 mg/kg/day). The multiple-dose vial of enoxaparin sodium contains 15 mg benzyl alcohol per 1 mL as a preservative [see Warnings and Precautions (5.8)]. anc <u>Data</u>

Human Data - There are no adequate and well-controlled studies in pregnant women. A retrospective study reviewed the records of 604 women who used enoxaparin during pregnancy. A total of 624 pregnancies resulted in 693 live births. There were 72 hemorrhagic events (11 serious) in 63 women. There were 14 cases of neonatal hemorrhage. Major congenital anomalies in live births occurred at rates (2.5%) similar to background rates.

There have been postmarkeling reports of fetal death when pregnant women received enoxaparin sodium. Causality for these cases has not been determined. Insufficient data, the underlying disease, and the possibility of inadequate anticoagulation complicate the evaluation of these cases.

A clinical study using enoxaparin in pregnant women with mechanical prosthetic heart valves has been conducted [see Warnings and Precautions (5.7).

Animal Data – Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 15 times the recommended human dose (by comparison with 2 mg/kg as the maximum recommended daily dose). There was no evidence of teratogenic effects or fetotoxicity due to enoxaparine. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

8.3 Nursing Mothers

It is not known whether enoxaparin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from enoxaparin, a decision should be made whether to discontinue nursing or discontinue enoxaparin sodium, taking into account the importance of enoxaparin sodium to the mother and the known benefits of nursing. 8.4 Pediatric Use

Safety and effectiveness of enoxaparin sodium in pediatric patients have not been established

8.5 Geriatric Use

Prevention of Deep Vein Thrombosis in Hip, Knee and Abdominal Surgery; Treatment of Deep Vein Thrombosis, Prevention of Ischemic Complications of Unstable Angina and Non-Q-wave Myocardial Infarction

of Unstable Angina and Non-Q-wave Myocardial Infarction Over 2800 patients, 65 years) was similar to that seen in younger patients (<65 years). The incidence of bleeding complications was similar between geriatric (<65 years) was similar to that seen in younger patients (<65 years). The incidence of bleeding complications was similar between geriatric (<65 years) was similar to that seen in younger patients (<65 years). The incidence of bleeding complications was similar between geriatric and younger patients when 30 mg every 12 hours or 40 mg once a day doese of enxaparin sodium was administered at doese of 1.5 mg/kg once a day or 1 mg/kg every 12 hours. The risk of enoxaparin-associated bleeding increased with age c. Serious adverse events increased with age for patients receiving enxoparin sodium. Other clinical experience (including postmarketing zuveillance and literature reports) has not revealed dividional differences in the safety of enoxaparin sodium between geriatric and younger patients. Careful attention to dosing intervals and concomitant medications (sepecially antiplatelet medications) is advised. Enoxaparin sodium should be used with care in geriatric patients who may show delayed elimination of enoxaparin. Monitoring of geriatric patients with how dow weight (<45 kg) and those predisposed to decreased enal function should be considered (see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3). <u>Tradiment of Acute 51-Segment Elevation Myocardial Infarction</u> In the clinical advide to traditment of acute 51-Segment elevation myocardial infarction.

Treatment of Acute ST-Segment Elevation Myocardial Infanction In the clinical study for treatment of acute ST-segment elevation myocardial infanction, there was no evidence of difference in efficacy between patients ₂/5 years of age (n = 1241) and patients less than 75 years of age (n=9015). Patients ₂/5 years of age (n = 1241) and patients less than 75 years of age (n=9016). Patients ₂/5 years of age (n = 1241) and patients less than 75 years of age (n=9016). Patients ₂/5 years of age (d not receive a 30 mg W bolus prior to the normal dosage regimen and had their SC dose adjusted to 0.75 mg/kg every 12 hours [see Dosage and Administration [2.3]. The incidence of bleeding complications was higher in patients ₂/65 years of age as compared to younger patients (<65 years). **8.6 Patients with Mechanical Prosthetic Heart Valves** The use of enoxaparin sodium has not been adequately studied for thromboprophylaxis in patients with mechanical prosthetic heart valves and has not been adequately studied for long-term use in this patient population. Isolated cases of prosthetic heart valve thrombosis have been reported in patients with mechanical prosthetic heart valves who have received enoxaparin for thromboprophylaxis. Some of these cases were pregnant vomen in whom thrombosis led to matemal and fetal deaths. Insufficient data, the underlying disease and the possibility of inadequate anticoaquitation complicate the evaluation of these cases. Pregnant women with mechanical prosthetic heart valves may be at higher risk for thromboembolism [see Warnings and Precautions (5.7)].

8.7 Renal Impairment

6.7 Herail impairment In patients with renal impairment, there is an increase in exposure of enoxaparin sodium. All such patients should be observed carefully for signs and symptoms of bleeding. Because exposure of enoxaparin sodium is significantly increased in patients with severe renal impairment (creatinne clearance <30 mL/min), a dosage adjustment is recommended for threapeutic and prophylactic dosage angus. No dosage adjustment is recommended in patients with moderate (creatinne clearance 9.0-50 mL/min) and mild (creatinne clearance 50-80 mL/min) renal impairment (see additional clearance size) and clinical Pharmacology (12.3). In patients with renal failure, treatment with enoxaparin sodium has been associated with the development of hyperkalemia [see Adverse Reactions (6.2)].

associated with the dereloptient of hyberkalenia (see nurse reactions (c.2)). 8.8 Hepatic Impairment The impact of hepatic impairment on enoxaparin's exposure and antithrombotic effect has not been investigated. Caution should be exercised when administering enoxaparin sodium to patients with hepatic impairment.

8.9 Low-Weight Patients

An increase in exposure of enoxaparin sodium with prophylactic dosages (non-weight adjusted) has been observed in low-weight women (<45 kg) and low-weight men (<57 kg). All such patients should be observed carefully for signs and symptoms of bleeding [see *Clinical Pharmacology* (12.3]).

(BMC second and the second sec signs and symptoms of thromboembolism.

10 OVERDOSAGE

10 UVENUOSAGE Accidental overdosage following administration of enoxaparin sodium may lead to hemorrhagic complications. Injected enoxaparin sodium may be largely neutralized by the slow IV injection of protamine sulfate (1% solution). The dose of protamine sulfate should be equal to the dose of enoxaparin sodium injected: 1 mg protamine sulfate should be administered to neutralize 1 mg enoxaparin sodium was administered in the previous 8 hours. An infusion of 0.5 mg protamine per 1 mg of enoxaparin sodium may be administered if enoxaparin sodium was administered greater than 8 hours previous to the protamine administration, or if it has been determined that a second dose of protamine is required. The second infusion of 0.5 mg protamine sulfate per 1 mg of enoxaparin sodium may be administered if the aPTT measured 2 to 4 hours after the first infusion permiser monored. after the first infusion remains prolonged

after the first intision remarks protonged. If at least 12 hours have elapsed since the last enoxaparin sodium injection, protamine administration may not be required; however, even with higher doses of protamine, the aPTT may remain more prolonged than following administration of heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60%). Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions, often resembling anaphylaxis, have been reported with protamine sulfate, it should be given only when resuccitation techniques and treatment of anaphylactic shock are readily available. For additional information consult the labeling of protamine sulfate injection products.

11 DESCRIPTION


Enoxaparin sodium nipetion is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. The pH of the injection is 5.5 to 7.5.


Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. Its structure Exception solution is contact by action dependence of the provided of the provided in the prov

≤20%

<2000 daltons

STRUCTURAL FORMULA





Enoxaparin sodium injection 100 mg/mL Concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU (with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard)) per 0.1 mL Water for Injection.

Enoxaparin sodium injection 150 mg/mL Concentration contains 15 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1500 IU (with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard)) per 0.1 mL Water for Injection. The enoxaparin sodium prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. The multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative [see Dosage and Administration (2) and How

injection. The Supplied (16) CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Enoxaparin is a low molecular weight heparin which has antithrombotic properties.

Encogapari is a low molecular weight heparin which has antithrombotic properties. **12.2 Pharmacodynamics** In humans, encovaparin sodium given at a dose of 1.5 mg/kg subcutaneously (SC) is characterized by a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean \pm SD, 14.0 \pm 3.1) (based on areas under anti-Factor activity versus time curves) compared to the ratios observed for heparin (mean-SD, 1.24 \pm 0.13). Increases of up to 1.8 times the control values were seen in the thrombin time (TT) and the activited patients in a large clinical trial resulted in aPTT values of 45 seconds or less in the majority of patients (n = 1607), A 30 mg IV bolus immediately followed by a 1 mg/kg SC administration resulted in aPTT post-injection values of 50 seconds. The average aPTT prolongation value on Day 1 was about 163 Democraceholistic

12.3 Pharmacokinetics

12.3 Pharmacokinetics <u>Absorption</u>: Pharmacokinetic trials were conducted using the 100 mg/mL formulation. Maximum anti-Factor Xa and anti-thrombin (anti-Factor IIa) <u>activities occur</u> 3 to 5 hours after SC injection of enoxaparin sodium. Mean peak anti-Factor Xa activity was 0.16 IU/mL (1.58 mcg/mL) and 0.38 IU/ mL (3.53 mcg/mL) after the 20 mg and the 40 mg clinically tested SC doese, respectively. Mean (n = 46) peak anti-Factor Xa activity was 1.1 IU/mL at steady state in patients with unstable angina reveniving 1 mg/kg SC every 12 hours for 14 days. Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given SC, based on anti-Factor Xa activity is approximately 100% in healthy subjects. A 30 mg V bolus immediately followed by a 1 mg/kg SC every 12 hours provided initial peak anti-Factor Xa levels of 1.16 IU/mL (n=16) and average exposure corresponding to 84% of steady-state levels. Steady state is achieved on the second day of treatment. Enoxaparin pharmacokinetics appear to be linear over the recommended dosage ranges [see *Dosage and Administration (2)]*. After repeated subcuraneous administration of 40 mg once daily and 1.5 mg/kg once-daily reglimens in healthy volunteers, the steady state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. Steady-state enoxaparin activity levels are well predicted by single-dose pharmacokinetics. After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady state is reached from day 4 with maen exposure about 65% higher than after a single dose and mean peak and trough levels daily regimen. The steady state is eached from day 4 with maen exposure about 65% higher than after a single dose and mean peak and trough levels daily regimen, the steady state is eached from day 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels daily regimen, the steady state is eached from day 4 with mean exposure about 65% higher than after a single dose and maen peak an

Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium to water by projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin dose. When a daily 1.5 mg/kg SC injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration the following pharmacokinetic profiles were obtained [see Table 13].

enoxaparin sodium injection

Table 13 Pharmacokinetic Parameters* After 5 Days of 1.5 mg/kg SC Once Daily Doses of Enoxaparin Sodium Using 100 mg/mL *or* 200 mg/mL Concentrations

	-		-		
	Concentration	Anti-Xa	Anti-Ila	Heptest	aPTT
A _{max} (IU/mL or Δ sec)	100 mg/mL	1.37 (±0.23)	0.23 (±0.05)	105 ([±] 17)	19 (±5)
	200 mg/mL	1.45 (±0.22)	0.26 (±0.05)	111 (±17)	22 (±7)
	90% CI	102-110%		102-111%	
t _{max} ** (h)	100 mg/mL	3 (2-6)	4 (2-5)	2.5 (2-4.5)	3 (2-4.5)
	200 mg/mL	3.5 (2-6)	4.5 (2.5-6)	3.3 (2-5)	3 (2-5)
AUC (ss) (h*IU/mL or h* ∆ sec)	100 mg/mL	14.26 (±2.93)	1.54 (±0.61)	1321 (±219)	
	200 mg/mL	15.43 (±2.96)	1.77 ([±] 0.67)	1401 (±227)	
	90% CI	105-112%		103-109%]

*Means ± SD at Day 5 and 90% Confidence Interval (CI) of the ratio

Distribution: The volume of distribution of anti-Factor Xa activity is about 4.3 L.

<u>Distructions</u>: The Volume of distribution of anti-Factor Aa activity is adout 4.3. C. <u>Elimination</u>: Tollowing intravenous (IV) dosing, the total body clearance of enoxaparin is 26 mL/min. After IV dosing of enoxaparin labeled with the gamma-emitter, ^{gam}Tc, 40% of radioactivity and 8 to 20% of anti-Factor Xa activity were recovered in urine in 24 hours. Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single SC dose to about 7 hours after repeated dosing. Significant anti-Factor Xa activity persists in plasma for about 12 hours following a 40 mg SC once a day dose. Following SC dosing, the apparent clearance (CL/F) of enoxaparin is approximately 15 mL/min.

Metabolism: Towards of the second of the sec

Special Populations

Gender: Appendix Gender: Appendix Clearance and Amax derived from anti-Factor Xa values following single SC dosing (40 mg and 60 mg) were slightly higher in males than in females. The source of the gender difference in these parameters has not been conclusively identified; however, body weight may be a contributing factor.

Geriatric: Apparent clearance and A_{max} derived from anti-Factor Xa values following single and multiple SC dosing in geriatric subjects were close to those observed in young subjects. Following once a day SC dosing of 40 mg enoxaparin sodium, the Day 10 mean area under anti-Factor Xa activity versus time curve (AUC) was approximately 15% greater than the mean Day 1 AUC value (see *Dosage and Administration (2.3)* and Use in Specific Populations (8.5).

in Specific Populations (8.5). Renal Impairment: A linear relationship between anti-Factor Xa plasma clearance and creatinine clearance at steady state has been observed, which indicates decreased clearance of enoxaparin in patients with reduced renal function. Anti-Factor Xa exposure represented by AUC, at steady state, is marginally increased in mild (creatinine clearance 50-80 mU/min) and moderate (creatinine clearance 30-50 mU/min) renal impairment after repeated subcitaneous 40 mg once-daily doses. In patients with severe renal impairment (creatinine clearance <30 mU/min), the AUC at steady state is significantly increased on average by 65% after repeated subcitaneous 40 mg once-daily doses [see Dosage and Administration (2.2) and Use in Specific Populations (2.7).

Hemodialysis: In a single study, elimination rate appeared similar but AUC was two-fold higher than control population, after a single 0.25 or 0.5 mg/kg intravenous dose

or 0.5 mg/kg intravenous dose. Hepatic Impairment: Studies with enoxaparin sodium in patients with hepatic impairment have not been conducted and the impact of hepatic impairment on the exposure to enoxaparin is unknown [see Use in Specific Populations (8.8)]. Weight: After repeated subcutaneous 1.5 mg/kg once daily dosing, mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy volunteers (BM 30-48 kg/m²) compared to non-obese control subjects, while A_{max} is not increased. When non-weight adjusted dosing was administered, it was found after a single-subcutaneous 40 mg dose, that anti-Factor Xa exposure is 52% higher in low-weight women (<57 kg) and 27% higher in low-weight men (<57 kg) when compared to normal weight control subjects [see Use in Specific Populations (8.9).

Pharmacokinetic interaction: No pharmacokinetic interaction was observed between enoxaparin and thrombolytics when administered

13 NONCLINICAL TOXICOLOGY

13 NONCLINICAL TOXICOLOGY 3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not mutagenic in *in wiro* tests, including the Ames test, mouse lymphoma cell forward mutation test, and human hymphocyte chromosomal aberration test, and the *in wiro* tasts, including the Ames test, mouse lymphoma cell forward mutation test, and human hymphocyte chromosomal aberration test, and the *in wiro* tasts. Stock and been any imphore the complexity of the angle of the stock and the in average body weight of 70 kg, height of 170 cm, and body surface area of 1.8 m²).
3.2 Animal Toxicology and/or Pharmacology
A single SC dose of 46.4 mg/kg enoxaparin was lethal to rats. The symptoms of acute toxicity were ataxia, decreased motility, dyspnea, cyanosis, and coma

and coma. 13.3 Reproductive and Developmental Toxicology

Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 30 mg/kg/day corresponding to 211 mg/ m²/day and 410 mg/m²/day in rats and rabbits respectively. There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin. 14 CLINICAL STUDIES

14.1 Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications

Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longe than 30 minutes or who have additional risk factors such as malignancy or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) trian 30 minutes of who nave additional risk ractors such as malignancy of a instory of deep vein intromosis (VII) or plumonary emotions (III) in a double-bind, parallel group subdy of patients undergoing elective cancer supery of the gastrointestinal, urological, or gynecological tract, a total of 1116 patients were enrolled in the study, and 1115 patients were treated. Patients ranged in age from 32 to 97 years (mean age 67 years) with 52.7% men and 47.3% women. Patients were 98% Caucasian, 11% Black, 0.4% Asian and 40.4% others. Encoaparin sodium 40 mg 50, cadministered once a day, beginning 2 hours prior to surgery and continuing for a maximum of 12 days after surgery, was comparable to heparin 5000 U every 8 hours SC in reducing the risk of DVT. The efficacy data are provided below [see Table 14].

Table 14 Efficacy of Enoxaparin Sodium in the Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery

	Dosir	Dosing Regimen		
Indication	Enoxaparin Sodium 40 mg q.d. SC n (%)	Heparin 5000 U q8h SC n (%)		
All Treated Abdominal Surgery Patients	555 (100)	560 (100)		
Treatment Failures Total VTE ¹ (%)	56 (10.1) (95% Cl ² : 8 to 13)	63 (11.3) (95% Cl: 9 to 14)		
DVT Only (%)	54 (9.7) (95% Cl: 7 to 12)	61 (10.9) (95% Cl: 8 to 13)		

¹ VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin

In a second double-blind, parallel group study, enoxaparin sodium 40 mg SC once a day was compared to heparin 5000 U every 8 hours SC in patients undergoing colorectal surgery (one-third with cancer). A total of 1347 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 50.1 years) with 54.2% men and 45.8% women. Treatment was initiated approximately 7 to 10 days after surgery. The efficacy data are provided below (see Table 15).

Table 15 Efficacy of Enoxaparin Sodium in the Prophylaxis of Deep Vein Thrombosis Following Colorectal Surgery

	Dosing R	legimen
Indication	Enoxaparin Sodium 40 mg q.d. SC n (%)	Heparin 5000 U q8h SC n (%)
All Treated Colorectal Surgery Patients	673 (100)	674 (100)
Treatment Failures Total VTE ¹ (%)	48 (7.1) (95% Cl ² : 5 to 9)	45 (6.7) (95% Cl: 5 to 9)
DVT Only (%)	47 (7.0) (95% CI: 5 to 9)	44 (6.5) (95% Cl: 5 to 8)

8

VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin 2 Cl - Confidence Interval

14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Enoxaparin sodium has been shown to reduce the risk of post-operative deep vein thrombosis (DVT) following hip or knee replacement surgery. In a double-billind study, enoxyaprin sodium 30 merel per solution code your intomicing (or n) notifient proteins and only a solution of the s Table 16

Efficacy of Enoxaparin Sodium in the Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery

	Dosing Reg	Dosing Regimen		
Indication	Enoxaparin Sodium 30 mg q12h SC n (%)	Placebo q12h SC n (%)		
All Treated Hip Replacement Patients	50 (100)	50 (100)		
Treatment Failures Total DVT (%)	5 (10) ¹	23 (46)		
Proximal DVT (%)	1 (2) ²	11 (22)		

p value versus placebo = 0.0002 ² p value versus placebo = 0.0134

A double-bind, multicenter study compared three dosing regimens of enoxaparin sodium in patients with hip replacement. A total of 572 patients were randomized in the study and 568 patients were treated. Patients ranged in age from 31 to 88 years (mean age 647 years) with 6% mean ad37% women. Patients were 93% causain 6% Black, -1% kaisi, and 1% others. Treatment was initiated within two days after surgery and was continued for 7 to 11 days after surgery. The efficacy data are provided below [see Table 17].

Table 17

Efficacy of Enoxanarin Sodium in the Pronhylaxis of Deen Vein Thromhosis Following Hin Replacement Surgery

		Dosing Regimen		
Indication	10 mg q.d. SC n (%)	30 mg q12h SC n (%)	40 mg q.d. SC n (%)	
All Treated Hip Replacement Patients	161 (100)	208 (100)	199 (100)	
Treatment Failures Total DVT (%)	40 (25)	22 (11)1	27 (14)	
Proximal DVT (%)	17 (11)	8 (4)2	9 (5)	

 1 p value versus enoxaparin sodium 10 mg once a day = 0.0008 2 p value versus enoxaparin sodium 10 mg once a day = 0.0168 2

² p value versus enoxaparin solumi to mg once a day = 0.0168 There was no significant difference between the 30 mg every 12 hours and 40 mg once a day regimens. In a double-blind study, enoxaparin sodium 30 mg every 12 hours SC was compared to placebo in patients undergoing knee replacement surgery. A total of 132 patients were randomized in the study and 131 patients were treated, of which 99 had total knee replacement and 32 had either unicompartmental knee replacement or tibial osleotomy. The 99 patients with total knee replacement ranged in age from 42 to 85 years (mean age 702 years) with 36.4% men and 65.6% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued up 15 days after surgery. The indence of proximal and total DVT after surgery was significantly lower for enoxaparin sodium compared to placebo. The efficacy data are provided below [see Table 18].

Table 18 Efficacy of Enoxaparin Sodium in the Prophylaxis of Deep Vein Thrombosis Following Total Knee Replacement Surgery

	Dosing Regimen		
Indication	Enoxaparin Sodium 30 mg q12h SC n (%)	<u>Placebo</u> q12h SC n (%)	
All Treated Total Knee Replacement Patients	47 (100)	52 (100)	
Treatment Failures Total DVT (%)	5 (11) ¹ (95% CI ² : 1 to 21)	32 (62) (95% Cl: 47 to 76)	
Proximal DVT (%)	0 (0) ³ (95% Upper CL ⁴ : 5)	7 (13) (95% Cl: 3 to 24)	

p value versus placebo = 0.0001

² Cl = Confidence Interval

³ p value versus placebo = 0.013 ⁴ CL = Confidence Limit

⁴ CL = Confidence Limit Additionally, in an open-label, parallel group, randomized clinical study, enoxaparin sodium 30 mg every 12 hours SC in patients undergoing elective knee replacement surgery was compared to heparin 5000 U every 8 hours SC. A total of 453 patients were randomized in the study and all were treated. Patients ranged in age from 38 to 90 years (mean age 68.5 years) with 43.7% men and 56.3% women. Patients were 92.5% Caucasian, 5.3% Black, and 0.6% others. Treatment was initiated after surgery and confinued up to 14 days. The indéence of deep vein thrombosis was significantly lower for enoxaparin sodium compared to heparin. Extended Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery. In a study of extended prophylaxis for patients undergoing hip replacement surgery, patients were treated, while hospitalized, with enoxaparin sodium 40 mg SC, initiated up to 12 hours prior to surgery for the prophylaxis of post-operative DVT. At the end of the peri-operative period, all patients undergore regimen of either enoxaparin sodium do mg (n = 90) once a day SC or to placeho (n = 80) for 3 weeks. A total ol 179 patients were treated in the double-blind phase of the study and all patients were treated. Patients ranged in age from 47 to 87 years (mean age 69.4 years) with 57% men and 43% women. In this population of patients, the incidence of DVT during extended prophylaxis was significantly lower for enoxaparin sodium compared to placeho. The efficacy data are provide before level. See Table 19. are provided below [see Table 19]

Table 19 Efficacy of Enoxaparin Sodium in the Extended Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery

	Post-Discharge Dosing Regimen		
Indication (Post-Discharge)	Enoxaparin Sodium 40 mg q.d. SC n (%)	Placebo q.d. SC n (%)	
All Treated Extended Prophylaxis Patients	90 (100)	89 (100)	
Treatment Failures Total DVT (%)	6 (7) ¹ (95% Cl ² : 3 to 14)	18 (20) (95% Cl: 12 to 30)	
Proximal DVT (%)	5 (6) ³ (95% CI: 2 to 13)	7 (8) (95% Cl: 3 to 16)	

1 p value versus placebo = 0.008

² Cl= Confidence Interval

³ p value versus placebo = 0.537

³ p value versus placebe = 0.537 In a second study, patients undergoing hip replacement surgery were treated, while hospitalized, with enoxaparin sodium 40 mg SC, initiated up to 12 hours prior to surgery. All patients were examined for clinical signs and symptoms of venous thromboembolic (VTE) disease. In a double-blind design, patients without clinical signs and symptoms of VTE disease were randomized to a post-discharage regimen of either enoxaparin sodium 40 mg (n = 131) once a day SC or to placebo (n = 131) for 3 weeks. A total of 262 patients were randomized in the study double-blind phase and all patients were treated. Patients ranged in age from 44 to 87 years (mean age 68.5 years) with 43.1% men and 56.9% women. Similar to the first study the incidence of DVT during extended prophysicax was significantly lower for enoxaparin sodium compared to placebo, with a statistically significant difference in both total DVT (enoxaparin sodium 21 [16%] versus placebo 45 [34%]; p = 0.001) and proximal DVT (enoxaparin sodium 8 [6%] versus placebo 28 [21%]; p = <0.001).</p>

14.3 Prophylaxis of Deep Vein Thrombosis in Medical Patients with Severely Restricted Mobility During Acute Illness In a double blind multicenter, parallel group study, enoxparin sodium 20 mg or 40 mg ore a day SC was compared to placebo in the prophylaxis of deep vein thrombosis (DVT) in medical patients with severely restricted mobility during acute illness (defined as walking distance of <10 meters for <3 days). This study included patients with heart failure (WHA Class III or IV); acute respiratory failure or complicated chronic respiratory insufficiency (not requiring ventilatory support): acute infection (excluding septic shock); or acute rheumatic disorder [acute lumbar or scatic pain, vertebral compression (due to osteoporosis or tumor), acute arthritic episodes of the lower extremities]. A total of 1102 patients were enrolled in the study, and 1073 patients were treated. Patients ranged in age from 40 to 97 years (maan age 73 years) with equal proportions of men and women. Treatment continued for a maximum of 14 days (mealan duration 7 days). When given at a dose of 40 mg once a day SC, enoxparin sodium significantly reduced the incidence of DVT as compared to placebo. The efficacy data are provided below [see Table 20].

enoxaparin sodium injection

Efficacy of Enoxaparin Sodium in the Prophylaxis of Deep Vein Thrombosis in Medical Patients with Severely Restricted Mobility During Acute Illness

	Dosing Regimen		
Indication	Enoxaparin Sodium 20 mg q.d. SC n (%)	Enoxaparin Sodium 40 mg q.d. SC n (%)	<u>Placebo</u> n (%)
All Treated Medical Patients During Acute Illness	351 (100)	360 (100)	362 (100)
Treatment Failure ¹ Total VTE ² (%)	43 (12.3)	16 (4.4)	43 (11.9)
Total DVT (%)	43 (12.3) (95% Cl ³ 8.8 to 15.7)	16 (4.4) (95% Cl ³ 2.3 to 6.6)	41 (11.3) (95% Cl ³ 8.1 to 14.6)
Proximal DVT (%)	13 (3.7)	5 (1.4)	14 (3.9)

¹ Treatment failures during therapy, between Days 1 and 14

² VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin ³ CI = Confidence Interval

At approximately 3 months following enrollment, the incidence of venous thromboembolism remained significantly lower in the enoxaparin 40 mg tment group versus the placebo treatment group.

treatment group versus the placebo treatment group. 14.4 Treatment of Doep Vein Trombosis with or without Pulmonary Embolism In a multicenter, parallel group study, 900 patients with acute lower extremity deep vein thrombosis (DVT) with or without pulmonary embolism (PE) were randomized to an inpatient (hospital) treatment of either (i) enoxaparin sodium 1.5 mg/kg once a day S/C, (ii) enoxaparin sodium 1 mg/ kg every 12 hours S/C, or (iii) heparin IV blous (S000 UI) followed by a continuous infision (administered to achieve an aPTI of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 by Symome. All patients also received wardarin sodium (dose adjusted according to PT to achieve an International Normalization Ratio (INR) of 2.0 to 3.0), commencing within 72 hours of initiation of enoxaparin sodium or standard heparin therapy, and continuing for 90 days. Enoxaparin sodium or standard heparin therapy was administered for a minimum of 5 days and until the targeted wardarin sodium thromboembolism (0VT and/or PE). The efficacy data are provided below (see Table 21). Table 21

Table 21 Efficacy of Enoxaparin Sodium in Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism

	Dosing Regimen ¹		
Indication	<u>Enoxaparin</u> <u>Sodium</u> 1.5 mg/kg q.d. SC	Enoxaparin Sodium 1 mg/kg q12h SC	Heparin aPTT Adjusted IV Therapy n (%)
Indication	n (%)	n (%)	11 (70)
All Treated DVT Patients with or without PE	298 (100)	312 (100)	290 (100)
Patient Outcome Total VTE ² (%)	13 (4.4) ³	9 (2.9) ³	12 (4.1)
DVT Only (%)	11 (3.7)	7 (2.2)	8 (2.8)
Proximal DVT (%)	9 (3.0)	6 (1.9)	7 (2.4)
PE (%)	2 (0.7)	2 (0.6)	4 (1.4)

¹ All patients were also treated with warfarin sodium commencing within 72 hours of enoxaparin sodium or standard heparin therapy. ² VTE = venous thromboembolic event (DVT and/or PE)
 ³ The 95% Confidence Intervals for the treatment differences for total VTE were:

Enoxaparin sodium once a day versus heparin (-3.0 to 3.5)

Enoxaparin sodium every 12 hours versus heparin (-4.2 to 1.7).

Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to enoxaparin sodium or heparin, Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to encorpaprin sodium or heparin. Patients who could not receive outpatient herapy were excluded from entering the study. Outpatient exclusion criteria included the following: inability to receive outpatient heparin therapy because of associated co-morbid conditions or potertial for non-compliance and inability to attend follow-up visits as an outpatient because of geographic inaccessibility. Eligible patients could be treated in the hospital, but ONLY envaparin patients were permitted to go home on therapy (72%). A total of 501 patients were randomized to the study and all patients were treated. Patients ranged in age from 19 to 96 years (mean age 57.8 years) with 60.5% mer and 39.5% women. Patients were randomized to either envaparin sodium 1 mg/kg every 12 hours SC or heparin IV bolus (5000 UI) followed by a continuous intusion administered to achieve an PTT of 60 to 85 seconds (in-patient treatment). All patients also received varfarin sodium as described in the previous study. Envaparin sodium or standard heparin therapy was administered to a minimum of 5 days. Envaparin sodium was equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism. The efficacy data are provide below (see Table 22].

Table 22 Efficacy of Enoxaparin Sodium in Treatment of Deep Vein Thrombosis

		Dosing Regimen ¹			
		Enoxaparin Sodium 1 mg/kg q12h SC	<u>Heparin</u> aPTT Adjusted IV Therapy		
Indication		n (%)	n (%)		
All Treated DVT Patients		247 (100)	254 (100)		
Patient Outcome Total VTE ² (%)		13 (5.3) ³	17 (6.7)		
	DVT Only (%)	11 (4.5)	14 (5.5)		
	Proximal DVT (%)	10 (4.0)	12 (4.7)		
	PE (%)	2 (0.8)	3 (1.2)		

1 All patients were also treated with warfarin sodium commencing on the evening of the second day of enoxaparin sodium or standard heparin therapy.

² VTE = venous thromboembolic event (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]).

The system conditioner interview of the free monitories of the system of the system of the system of the system of the free free for the law of the system of the free for the law of the system of the

14.5 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction In a multicentry double-billor, parallel groups ytury, patients who recently experienced unstable angina or non-Q-wave myocardial infarction were randomized to either enoxaparin sodium 1 mg/kg every 12 hours SC or heparin I/ bolus (5000 U) followed by a continuous infusion (adjusted to achieve an aPTT of 55 to 85 seconds). A total of 3171 patients were rerolled in the study, and 3107 patients were treated. Patients ranged in age from 25-94 years (median age 64 years), with 33.4% of patients the female and 66.6% male. Race was distributed as follows: 89.3% Caucasian, 43% Black, 2.0% Asian, and 3.5% other. All patients were treated with aspirin 100 to 325 mg per day. Treatment was initiated within 24 hours of the event and continue until clinical stabling procedures, or hospital discharge, with a maximal duration of 8 days of therapy. The combined incidence of the triple endpoint of each, myocardial infarction, or recurrent angina was lower for enoxaparin softum compared with heparin therapy at 14 days after initiation of the lower indence of the triple endpoint was sustained up to 30 days after initiation of treatment. These results were observed in an analysis of both all-randomized and all-treated patients. The efficacy data are provided below (see Table 23).

Table 23 Table 23 Efficacy of Enoxaparin Sodium in the Prophylaxis of Ischenic Complications in Unstable Angina and Non-O-Wave Mycardial Infarction (Combined Endpoint of Death, Myocardial Infarction, or Recurrent Angina)

	Dosing R	egimen ¹			
Indication	Enoxaparin Sodium 1mg/kg q12h SC n (%)	Heparin aPTT Adjusted IV Therapy n (%)	Reduction (%)	<u>p Value</u>	
All Treated Unstable Angina and Non-Q-Wave MI Patients	1578 (100)	1529 (100)			
Timepoint ² 48 Hours	96 (6.1)	112 (7.3)	1.2	0.120	
14 Days	261 (16.5)	303 (19.8)	3.3	0.017	
30 Days	313 (19.8)	358 (23.4)	3.6	0.014	

¹ All patients were also treated with aspirin 100 to 325 mg per day.

² Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days)

The combined incidence of death or myocardial infarction at all time points was lower for enoxaparin sodium compared to standard heparin therapy, but did not achieve statistical significance. The efficacy data are provided below [see Table 24].

Table 24 Table 24 Efficacy of Enoxaparin Sodium in the Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myccardial Infarction (Combined Endoaint of Death or Myccardial Infarction)

(combined Endpoint of Dealt of Myocardian Infarction)					
	Dosing R	egimen ¹			
Indication	Enoxaparin Sodium 1 mg/kg q12h SC n (%)	Heparin aPTT Adjusted IV Therapy n (%)	Reduction (%)	<u>p Value</u>	
All Treated Unstable Angina and Non-Q-Wave MI Patients	1578 (100)	1529 (100)			
Timepoint ² 48 Hours	16 (1.0)	20 (1.3)	0.3	0.126	
14 Days	76 (4.8)	93 (6.1)	1.3	0.115	
30 Davs	96 (6 1)	118 (7 7)	16	0.069	

¹ All patients were also treated with aspirin 100 to 325 mg per day.

² Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).

In a survey one year following treatment, with information available for 92% of enrolled patients, the combined incidence of death, myocardial infarction, or recurrent angina remained lower for enoxaparin sodium versus heparin (32.0% vs 35.7%). Urgent revascularization procedures were performed less frequently in the enoxaparin group as compared to the heparin group, 6.3% compared to 8.2% at 30 days (p = 0.047).

14.6 Treatment of Acute ST-Segment Elevation Myocardial Infarction

14.6 Treatment of Acute ST-Segment Elevation Myocardial Infarction In a multicenter, double-bind, double-dummy, parallel group study, patients with acute ST-segment elevation myocardial infarction (STEMI) who were to be hospitalized within 6 hours of onset and were eligible to receive fibrinolytic therapy were randomized in a 1:1 ratio to receive either enoxaparin sodium or unfractionated heparin. Study medication was initiated between 15 minutes before and 30 minutes after the initiation of fibrinolytic therapy. Unfractionated heparin was administered beginning with an 1 Volus of 60 UKg (maximum 4000 U) and followed with an infusion of 12 UKg per hour (initial maximum 1000 U per hour) that was adjusted to maintain an aPTT of 1.5 to 2 times the control value. The V infusion was to be given for at least 48 hours. The enoxaparin dosing strategy was adjusted according to the patient's age and renal function. For patients younger than 75 years of age, enoxaparin sodium was given as a single 30 mg intravenous bolus plus a 1 mg/kg SC dose followed by an SC ingection of 1 mg/kg every 12 hours. The or patients at least 75 years of age, the IV bolus was not given and the SC dose was reduced to 0.75 mg/kg every 12 hours. For patients insufficiency (estimated creatinic celarance of less than 30 mL per iminule), the dose was to be modified to 1 mg/kg every 24 hours. The 2 injections of enoxaparin sodium was 6.6 days. The mean treatment duration of unfractionated heparin was 4.4 hours.

duration for enoxaparin sodium was 6.6 days. The mean treatment duration of unfractionated heparin was 5.4 hours. When percutaneous cononary intervention was performed during study medication period, patients received antithrombotic support with blinded study drug. For patients on enoxaparin sodium, the PCI was to be performed on enoxaparin (no switch) using the regimen established in previous studies, *i.e.* no additional dosing, if the last SC administration was less than 8 hours before balloon inflation, IV bolus of 0.3 mg/kg enoxaparin sodium if the last SC administration was more than 8 hours before balloon inflation. Molus of 0.3 mg/kg enoxaparin sodium (19% tenceteptases, 5% reteplases and 55% ateplase) and 20% received streptokinase. Among 20,479 patients in the ITT population, the mean age was 60 years, and 76% were male. Racial distribution was: 87% Caucasian, 9.8% Asian, 0.2% black, and 2.8% other. Medical history included previous MI (13%), hypertension (14%), diabetes (15%) and angiographic evidence of CAD (5%). Concomitant medication included aprim (95%), beta-blockers (86%), ACE inhibitors (78%), statins (70%) and clopidogrel (27%). The Mit at entry was anterior in 43%, non-anterior in 55%, and both in 1%.

The intervent year and/on in You's how method in You's and occur in You's cause or myocardial re-infarction in the first 30 days after randomization. Total follow-up was one year. The rate of the primary efficacy end point (death or myocardial re-infarction) was 9.9% in the enoxaparin group, and 12.0% in the unfractionated heparin group, a 17% reduction in the relative risk, (P=0.000003) [see Table 25].

Table 25

	Enoxaparin			P Value
	Sodium (N=10,256)	(N=10,223)	(95% CI)	
Outcome at 48 hours	n (%)	n (%)		
Death or Myocardial Re-infarction	478 (4.7)	531 (5.2)	0.90 (0.80 to 1.01)	0.08
Death	383 (3.7)	390 (3.8)	0.98 (0.85 to 1.12)	0.76
Myocardial Re-infarction	102 (1.0)	156 (1.5)	0.65 (0.51 to 0.84)	< 0.001
Urgent Revascularization	74 (0.7)	96 (Ò.9)	0.77 (0.57 to 1.04)	0.09
Death or Myocardial Re-infarction or Urgent Revascularization	548 (5.3)	622 (6.1)	0.88 (0.79 to 0.98)	0.02
Outcome at 8 Days				
Death or Myocardial Re-infarction	740 (7.2)	954 (9.3)	0.77 (0.71 to 0.85)	< 0.001
Death	559 (5.5)	605 (5.9)	0.92 (0.82 to 1.03)	0.15
Myocardial Re-infarction	204 (2.0)	379 (3.7)	0.54 (0.45 to 0.63)	< 0.001
Urgent Revascularization	145 (1.4)	247 (2.4)	0.59 (0.48 to 0.72)	< 0.001
Death or Myocardial Re-infarction or Urgent Revascularization	874 (8.5)	1181 (11.6)	0.74 (0.68 to 0.80)	<0.001
Outcome at 30 Days				
Primary efficacy endpoint				
(Death or Myocardial Re-infarction)	1017 (9.9)	1223 (12.0)	0.83 (0.77 to 0.90)	0.000003
Death	708 (6.9)	765 (7.5)	0.92 (0.84 to 1.02)	0.11
Myocardial Re-infarction	352 (3.4)	508 (5.0)	0.69 (0.60 to 0.79)	< 0.001
Urgent Revascularization	213 (2.1)	286 (2.8)	0.74 (0.62 to 0.88)	< 0.001
Death or Myocardial Re-infarction or Urgent Revascularization	1199 (11.7)	1479 (14.5)	0.81 (0.75 to 0.87)	<0.001

Note: Urgent revascularization denotes episodes of recurrent myocardial ischemia (without infarction) leading to the clinical decision to perform coronary revascularization during the same hospitalization. Of denotes confidence intervals. The beneficial effect of enoxaparin sodium on the primary end point was consistent across key subgroups including age, gender, infarct location, history of diabetes, history of prior myocardial infarction, fibrinolytic agent administered, and time to treatment with study drug (see Figure 1); however, it is necessary to interpret such subgroup analyses with caution. nistory of diabet it is necessor

Figure 1. Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroups


			Pala	ive Risk			
Subgroup	No. of		Reia	ive Kisk	UFH	Enox	Reduction
-	Patient	5			(%)	(%)	in Risk
Sex: Male	15696				10.1	8.2	18
Sex: Female	4783			- !	18.3	15.4	16
Age: <75 yrs	17947				9.9	7.8	20
Age: >=75 yrs	2532		_		26.3	24.8	6
Infarct location: Anterior	8933		-	_	14.0	12.5	11
Infarct location: Other	11400				10.2	7.9	23
Diabetes: No	17189			.	11.1	9.2	17
Diabetes: Yes	3060			-	17.1	13.6	20
Prior MI: No	17745			.	11.1	9.2	17
Prior MI: Yes	2659			- 1	17.8	14.3	20
Fibrinolytic agent: Streptokinase	4139			<u> </u>	11.8	10.2	13
Fibrinolytic agent: Fibrin-specific	16283				12.0	9.8	18
Time to treatment: <median< td=""><td>9899</td><td></td><td></td><td></td><td>11.3</td><td>8.7</td><td>23</td></median<>	9899				11.3	8.7	23
Time to treatment: >=Median	10394			—i	12.5	11.0	12
PCI in 30 Days: No	15763			-	11.4	9.7	15
PCI in 30 Days: Yes	4716				13.9	10.8	23
Overall	20479				12.0	9.9	17
	L	0.50	0.75	1.00	1.25	1.:	50
<	<		xaparin better		UFH b	etter	>

* The primary efficacy end point was the composite of death from any cause or myocardial re-infarction in the first 30 days. The overall treatment effect of enoxaparin sodium as compared to the unfractionated heparin is shown at the bottom of the figure. For each subgroup, the circle is proportional to the number and represents the point estimate of the treatment effect and the horizontal lines represent the 95 percent confidence intervals. This repetific fibring/tice agest and the encloques and replaces the time from the onset of symptoms to the administration of study drug (median, 3.2 hours).

581664 The beneficial effect of enoxaparin sodium on the primary end point observed during the first 30 days was maintained over a 12 month follow-up period (see Figure 2).

Figure 2 - Kaplan-Meier plot - death or myocardial re-infarction at 30 days - ITT population

enoxaparin sodium injection



There is a trend in favor of enoxaparin sodium during the first 48 hours, but most of the treatment difference is attributed to a step increase in the event rate in the UFH group at 48 hours (seen in Figure 2), an effect that is more striking when comparing the event rates just prior to and just subsequent to actual times of discontinuation. These results provide evidence that UFH was effective and that it would be better if used longer than 48 hours. There is a similar increase in endpoint event rate when enoxaparin was discontinued, suggesting that it too was discontinued.

too soon in this study. The rates of major bemorrhages (defined as requiring 5 or more units of blood for transfusion, or 15% drop in bematocrit or clinically over The rates of major hemaningles (befined as requiring 5 and 6 and 6

16 HOW SUPPLIED/STORAGE AND HANDLING

arin sodium injection is available in two concentrations [see Tables 26 and 27]: Table 26

100 mg/mL Co entratio

Dosage Unit / Strength ¹	Anti-Xa Activity ²	Package Size (per carton)	Label Color	NDC # 63323-
Prefilled Syringes ³				
30 mg/0.3 mL	3000 IU	10 syringes	Medium Blue	568-83
40 mg/0.4 mL	4000 IU	10 syringes	Yellow	568-87
Graduated Prefilled Syringes ³				
60 mg/0.6 mL	6000 IU	10 syringes	Orange	568-88
80 mg/0.8 mL	8000 IU	10 syringes	Brown	568-90
100 mg/1 mL	10,000 IU	10 syringes	Black	568-84
Multiple-Dose Vial ⁴				
300 mg/3 mL	30,000 IU	1 vial	Red	565-86

¹ Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Enoxaparin sodium 30 and 40 mg prefilled syringes, and 60, 80, and 100 mg graduated prefilled syringes each contain **10 mg enoxaparin sodium per 0.1 mL Water** prefilled syrir for Injection.

imate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard. Approx Each enoxaparin sodium prefilled syringe is for single, one-time use only and is affixed with a 27 gauge x 1/2 inch needle ⁴ Each enoxaparin sodium multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative.

Table 27 150 mg/mL Conce

roo migrine concontration							
Dosage Unit / Strength ¹	Anti-Xa Activity ²	Package Size (per carton)	Syringe Label Color	NDC # 63323-			
Graduated Prefilled Syringes ³							
120 mg / 0.8 mL	12,000 IU	10 syringes	Purple	569-90			
150 mg / 1 mL	15,000 IU	10 syringes	Navy Blue	569-84			

¹ Strength represents the number of milliorams of enoxaparin sodium in Water for Injection. Enoxaparin sodium 120 and 150 mg oraduated Porteging represents the indirate of initigatility of enviragiant southin model for injection. Enviragiant southin 120 and 130 mg gladue prefilled synthesis containt 150 mg enviragiant southin 150 mg gladue
 Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.

³ Each enoxaparin sodium graduated prefilled syringe is for single, one-time use only and is affixed with a 27 gauge x 1/2 inch needle

Store at 25°C (77°F): excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Do not store the multiple-dose vials for more than 28 days after the first use.

Keep out of the reach of children.

17 PATIENT COUNSELING INFORMATION

If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, they should be informed to watch for signs and symptoms of spinal or epidural hematoma, such as tingling, numbress (especially in the lower limbs) and muscular weakness. If any of these symptoms occur the patient should contact his or her physician immediately. Additionally, the use of aspirin and other NSAIDs may enhance the risk of hemorrhage. Their use should be discontinued prior to enoxaparin therapy whenever possible; if co-administration is essential, the patient's clinical and laboratory status should be closely monitored [see Drug Additionally, the use of aspirith a therapy whenever possible; if co *Interactions (7)*]. Patients should also be informed

- of the instructions for injecting enoxaparin sodium if their therapy is to continue after discharge from the hospitals
- It may take them longer than usual to stop bleeding. they may bruise and/or bleed more easily when they are treated with enoxaparin sodium. they should report any unusual bleeding, bruising, or signs of thrombocytopenia (such as a rash of dark red spots under the skin) to their physician (see Warnings and Precautions (5.1, 5.5).
- to tell their physicians and dentists they are taking enoxaparin sodium and/or any other product known to affect bleeding before any surgery is scheduled and before any new drug is taken [see Warnings and Prezautions (5.3)]. to tell their physicians and dentists of all medications they are taking, including those obtained without a prescription, such as aspirin or other NSAIDs [see Drug Interactions (7)].

Manufactured for:

Fresenius Kabi USA, LLC Lake Zurich, IL 6004

© 2014 sanofi-aventis U.S. LLC

451428 50111335

